Gaucher Disease Type 1 - 25 Studies Found
Recruiting |
: Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1) : Gaucher Disease Type 1 : 2015-08-21 : Drug: N-acetylcysteine 1800mg NAC twice daily (3600mg/day) orally for approximately 90 days. |
Completed |
: Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease : Type 1 Gaucher Disease : 2006-04-26 : Drug: miglustat miglustat oral capsules 100mg three times daily (TID) |
Not yet recruiting |
: Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease : Type 1 Gaucher Disease : 2016-09-23 : Drug: Elelyso 60 units/kg All patients receive Elelyso 60 units/kg. |
Completed |
: Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease : Gaucher Disease Type 1 : 2014-01-27 : Device: BeamMed Speed-of-Sound bone strength test at forearm BeamMed Speed-of-Sound bone strength test a |
Terminated |
: A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101 : Type 1 Gaucher Disease : 2009-04-02 : Drug: AT2101 225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days |
Completed |
: Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease :
|
Recruiting |
: GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 : Gaucher Disease Type 1-Gaucher Disease Type 3 : 2016-07-20 : Drug: GZ402671 Other Name: Venglustat |
Recruiting |
: The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease :
: 2015-07-28 : Drug: Velaglucerase alfa Enzyme replacement therapy |
Completed |
: A Long-Term Extension Study of AT2101 in Type 1 Gaucher Patients :
|